Intel, Core BTS, Salesforce, Verizon, ServiceNow, Cisco and Cyderes were among the tech companies making key executive hires ...

In its first quarter 2025 investor letter, ClearBridge Value Strategy emphasized stocks such as Gilead Sciences, Inc. (NASDAQ:GILD). Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company.

About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after ...

In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.

The most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily ...

Gilead Sciences, Inc. (GILD), based in Foster City, California, is a leading biopharmaceutical company focused on developing and commercializing groundbreaking therapies for diseases like HIV ...

Has Gilead Sciences (GILD) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with ...

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform ...

“It’s been more than five years and I’m getting the help I need thanks to my doctor.” Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes ...

The move: Gilead Sciences dropped 2.52% in premarket trading, falling to $107.45 per share Wednesday morning. The biopharmaceutical company is up 19.34% for the year. Why: The stock's decline ...